We will be comparing the differences between DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and Equillium Inc. (NASDAQ:EQ) as far as profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics Inc.	N/A	86.09	5.73M	-0.78	0.00
Equillium Inc.	N/A	0.00	13.25M	-0.71	0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics Inc.	0.00%	0%	0%
Equillium Inc.	0.00%	0%	0%

Institutional and Insider Ownership

Roughly 13.78% of DiaMedica Therapeutics Inc. shares are held by institutional investors while 27.1% of Equillium Inc. are owned by institutional investors. Insiders held roughly 17.35% of DiaMedica Therapeutics Inc.’s shares. Competitively, insiders own roughly 21.3% of Equillium Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
DiaMedica Therapeutics Inc.	-7.36%	-12.82%	-32%	-60.47%	-32.97%	16.84%
Equillium Inc.	13.92%	-14.33%	-51.67%	0%	0%	-7.72%

For the past year DiaMedica Therapeutics Inc. has 16.84% stronger performance while Equillium Inc. has -7.72% weaker performance.

Summary

On 3 of the 5 factors DiaMedica Therapeutics Inc. beats Equillium Inc.

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.